VCBeat Health Contact Us
Home BeiGene (Now BeOne) Announces RMB 446 Million Tax Adjustment, Reaffirms Financial Stability and Global Operations

BeiGene (Now BeOne) Announces RMB 446 Million Tax Adjustment, Reaffirms Financial Stability and Global Operations

Jun 26, 2026 19:28 CST Updated 19:28
BeOne

Developer of Molecular Targeted and Immune Anti-Tumor Drugs

百济神州;补税4.46亿元;回应

Image Source: Visual China Group

Interface News Reporter |Chen Yang

Interface News Editor |Xie Xin

After the market close on June 26, BeOne announced that, pursuant to a notice from the competent tax authorities regarding relevant tax matters, the company is required to pay back taxes and late payment fees totaling approximately RMB 446 million. BeOne stated that it will promptly and fully settle the aforementioned amounts in accordance with requirements, and that this matter does not involve any administrative penalties.

Meanwhile, BeOne stated that, after careful assessment, the aforementioned matters do not constitute prior-period accounting errors and do not involve retrospective adjustments to prior-period financial data. The supplemental payments are expected to be recognized in the company’s current profit or loss for 2026, with the specific impact on net profit attributable to parent company shareholders subject to the final audited financial statements for the 2026 fiscal year.

Additionally, according to the announcement, this matter of supplementary tax payment is not expected to have a significant adverse impact on BeOne’s financial condition, ability to continue operations, or the company’s normal business operations.

On the same day, BeOne responded to Jiemian News regarding the matter, stating that in addition to the contents of the announcement, the company has always prioritized compliant operations, will continue to fulfill its tax obligations in accordance with the law, and maintain effective communication with regulatory authorities.

BeOne, founded in Beijing in 2010, is a Chinese pharmaceutical company widely recognized within the industry for its independent international expansion and global operational capabilities. Its hematologic oncology products, zanubrutinib and sotoclax, as well as the PD-1 inhibitor tislelizumab for the treatment of solid tumors, have all received approval in both China and the United States.

However, with its English name changing from BeiGene to BeOne in 2025, the relocation of its headquarters to Switzerland, and a series of senior-level changes including Hillhouse’s recent exit from the board of directors, external observers have begun to question whether it remains a Chinese pharmaceutical company.

In terms of performance, BeOne’s revenue in 2025 reached RMB 38.225 billion, a year-on-year increase of 40.46%; net profit attributable to shareholders was RMB 1.461 billion, marking its first annual profit. Among its products, the flagship drug zanubrutinib generated RMB 28.067 billion in revenue, up 48.8% year on year, with the U.S. and Chinese markets contributing approximately 70% and 9% of sales, respectively.

Interface News Reporter |Chen Yang

Interface News Editor |Xie Xin

After the market close on June 26, BeOne announced that, pursuant to a notice from the competent tax authorities regarding relevant tax matters, the company is required to pay back taxes and late fees totaling approximately RMB 446 million. BeOne stated that it will promptly and fully settle the aforementioned amounts in accordance with requirements, and that this matter does not involve any administrative penalties.

Meanwhile, BeOne stated that, after careful assessment, the aforementioned matters do not constitute prior-period accounting errors and do not involve retrospective adjustments to prior-period financial data. The supplemental payments are expected to be recognized in the company’s current profit or loss for 2026, with the specific impact on net profit attributable to shareholders of the parent company subject to final determination based on the audited financial statements for the 2026 fiscal year.

Furthermore, according to the announcement, this matter of supplementary tax payment is not expected to have a significant adverse impact on BeOne's financial status, its ability to continue operations, or the company’s normal business activities.

On the same day, BeOne responded to Jiemian News regarding the matter, stating that in addition to the contents of the announcement, the company has always valued compliant operations, will continue to fulfill its tax obligations in accordance with the law, and maintain good communication with the relevant authorities.

BeOne, founded in Beijing in 2010, is a Chinese pharmaceutical company widely recognized within the industry for its independent international expansion and global operational capabilities. Its hematologic oncology products, zanubrutinib and sotoclax, as well as the PD-1 inhibitor tislelizumab for the treatment of solid tumors, have all received approval in both China and the United States.

However, with its English name changing from BeiGene to BeOne in 2025, the relocation of its headquarters to Switzerland, and a series of senior management changes including Hillhouse’s recent exit from the board of directors, external observers have begun to question whether it remains a Chinese pharmaceutical company.

In terms of performance, BeOne’s revenue reached RMB 38.225 billion in 2025, a year-on-year increase of 40.46%; net profit attributable to shareholders was RMB 1.461 billion, marking its first annual profit. Among these, the flagship product zanubrutinib generated revenue of RMB 28.067 billion, a year-on-year increase of 48.8%, with the U.S. and Chinese markets contributing approximately 70% and 9% of sales, respectively.

百济神州;补税4.46亿元;回应

Image source: Visual China

Interface News Reporter |Chen Yang

Jiemian News Editor |Xie Xin

After the market close on June 26, BeOne announced that, pursuant to a notice from the competent tax authorities regarding relevant tax matters, the Company is required to pay back taxes and late payment fees totaling approximately RMB 446 million. BeOne stated that it will promptly and fully settle the aforementioned amounts in accordance with the requirements, and that this matter does not involve any administrative penalties.

Meanwhile, BeOne stated that, after careful assessment, the aforementioned matters do not constitute prior-period accounting errors and do not involve retrospective adjustments to prior-period financial data. The supplemental payments are expected to be recognized in the company’s current profit or loss for 2026, with the specific impact on net profit attributable to shareholders of the parent company subject to final determination based on the audited financial statements for the 2026 fiscal year.

According to the announcement, the matter of supplementary tax payment is not expected to have a material adverse impact on BeOne’s financial position, ability to continue as a going concern, or normal business operations.

On the same day, BeOne responded to The Interface News regarding the matter, stating that in addition to the contents of the announcement, the company has always prioritized compliant operations, will continue to fulfill its tax obligations in accordance with the law, and maintain good communication with the relevant authorities.

BeOne, founded in Beijing in 2010, is a Chinese pharmaceutical company widely recognized within the industry for its independent international expansion and global operational capabilities. Its hematologic oncology products, zanubrutinib and sotoclax, as well as the PD-1 inhibitor tislelizumab for the treatment of solid tumors, have all received approval in both China and the United States.

However, with its English name changing from BeiGene to BeOne in 2025, the relocation of its headquarters to Switzerland, and a series of senior management changes including Hillhouse’s recent exit from the board of directors, external observers have begun to question whether it remains a Chinese pharmaceutical company.

In terms of performance, BeOne reported revenue of RMB 38.225 billion in 2025, a year-on-year increase of 40.46%; net profit attributable to shareholders was RMB 1.461 billion, marking its first annual profit. Among its products, the flagship drug zanubrutinib generated revenue of RMB 28.067 billion, up 48.8% year on year, with the U.S. and Chinese markets contributing approximately 70% and 9% of sales, respectively.

Interface News Reporter |Chen Yang

Jiemian News Editor |Xie Xin

After the market close on June 26, BeOne announced that, pursuant to a notice from the competent tax authorities regarding relevant tax matters, the company is required to pay back taxes and late fees totaling approximately RMB 446 million. BeOne stated that it will promptly and fully settle the aforementioned amounts in accordance with requirements, and that this matter does not involve any administrative penalties.

Meanwhile, BeOne stated that, after careful assessment, the aforementioned matters do not constitute prior-period accounting errors and do not involve retrospective adjustments to prior-period financial data. The supplementary payments are expected to be recognized in the company’s current profit or loss for 2026, with the specific impact on net profit attributable to parent company shareholders subject to the final audited financial statements for the 2026 fiscal year.

Furthermore, according to the announcement, the matter of supplementary tax payment is not expected to have a significant adverse impact on BeOne’s financial position, its ability to continue as a going concern, or the company’s normal operations.

On the same day, BeOne responded to Jiemian News regarding the matter, stating that in addition to the contents of the announcement, the company has always valued compliant operations, will continue to fulfill its tax obligations in accordance with the law, and maintain good communication with the relevant authorities.

BeOne, founded in Beijing in 2010, is a Chinese pharmaceutical company widely recognized within the industry for its independent international expansion and global operational capabilities. Its hematologic oncology products, zanubrutinib and sotoclax, as well as the PD-1 inhibitor tislelizumab for the treatment of solid tumors, have all received approval in both China and the United States.

However, with its English name changing from BeiGene to BeOne in 2025, the relocation of its headquarters to Switzerland, and a series of senior-level changes including Hillhouse’s recent exit from the board of directors, outsiders have begun to question whether it is still a Chinese pharmaceutical company.

In terms of performance, BeOne’s revenue reached RMB 38.225 billion in 2025, a year-on-year increase of 40.46%; net profit attributable to shareholders was RMB 1.461 billion, marking its first annual profit. Among its products, the flagship drug zanubrutinib generated RMB 28.067 billion in revenue, up 48.8% year on year, with the U.S. and Chinese markets contributing approximately 70% and 9% of sales, respectively.